source
- Triveni Bio secures $65M Series C as second eczema candidate enters clinical trialsTriveni Bio announced a $65 million Series C financing round aimed at supporting its ongoing development programs. The round was co‑led by Ascenta Capital and Janus Henderson Investors, with parti…
- Migraine biotech Vedana Therapeutics raises $46 million Series A to advance preclinical pipelineVedana Therapeutics, a new biotech focused on migraine, has announced its emergence from stealth mode after securing a Series A financing round. The company raised $46 million from investors, whic…